Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nordic study aims to settle debate on best Clot-Busting approach for lung embolism

NCT ID NCT07003646

Knowledge-focused Sponsor: Sahlgrenska University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking 220 adults across Nordic countries who receive either clot-dissolving drugs or a catheter-based procedure for a severe pulmonary embolism. Researchers are comparing how often each treatment leads to serious bleeding or death within 30 days. The goal is to provide real-world evidence on which approach is safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Alteplase
What this could lead to
If successful, this study could clarify which reperfusion method is safer and more effective for high-risk pulmonary embolism, guiding future treatment guidelines.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient selection and cannot prove cause and effect. The small size (220 participants) limits generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pulmonary embolism patients treated with catheter directed intervention or systemtic thrombolysis in hospitals in Sweden and Denmark where the former treatment modality is established.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All adult patients (≥18 years), including pregnant women, with verified (CTPA, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis * Informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies) Exclusion Criteria: * Ongoing enrolment in interventional catheter directed intervention trial * Surgical embolectomy as primary reperfusion treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary embolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Denmark

  • Danderyd Hospital

    RECRUITING

    Stockholm, Sweden

  • Karolinska University Hospital Huddinge

    RECRUITING

    Stockholm, Sweden

  • Karolinska University Hospital Solna

    RECRUITING

    Stockholm, Sweden

  • Linköping University Hospital

    RECRUITING

    Linköping, Sweden

  • Odense University Hospital

    RECRUITING

    Odense, Denmark

  • Rigshospitalet

    RECRUITING

    Copenhagen, Denmark

  • Sahlgrenska University Hospital

    RECRUITING

    Gothenburg, 41345, Sweden

  • Skåne University Hospital

    RECRUITING

    Lund, Sweden

  • Sunderby Hospital

    RECRUITING

    Luleå, Sweden

  • Södersjukhuset

    RECRUITING

    Stockholm, Sweden

  • Uppsala University Hospital

    NOT_YET_RECRUITING

    Uppsala, Sweden

  • Örebro University Hospital

    RECRUITING

    Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.